Podcasts about glaukos

Es geht weiter mit der Fahrt der Argonauten auf der Suche nach dem goldenen Vlies und in dieser Folge kommt es zu einigen Missverständnissen. Jason und seine Mannschaft werden von Kyzikos und den Dolionen gastfreundlich empfangen, doch einige sechsarmige Riesen, die “Erdgeborenen” Gegeneis werden von Hera aufgepeitscht und greifen an. Dann töten die Argonauten versehentlich die Falschen, vergessen kurz darauf auch noch Herakles und müssen ohne ihn weiterfahren. Triggerwarnung: Diese Episode behandelt Themen wie Krieg und Suizid. Mit: Argo, Argonauten, Jason, Pelias, Aietes, Herakles, Dolionen, Kyzikos, Kleite, Gegeneis, Erdgeborene, Poseidon, Hera, Zeus, Hylas, Polyphemos, Tiphys, Akastos, Mopsos, Pelasger, Rhea, Kalais, Zetes, Boreas, Glaukos, Orpheus, Cheiron, Achilles, Peleus, Thetis, Johann Heinrich Voß. Orte: Iolkos, Lemnos, Kolchis, Hellespont, Ägäis, Propontis, Marmarameer, Bärenberg, Phrygien. STEADY https://steadyhq.com/de/chaoskinder/about WERBEFREIER FEED https://open.spotify.com/show/5yF7oCMeJ9VuXNOKGI91ZS?si=6c90144399804043 PAYPAL https://www.paypal.com/donate/?hosted_button_id=VB2QKC88H9NYJ LITERATUR https://chaoskinderpodcast.wordpress.com/2022/06/27/quellen-und-literatur-auswahl/ MUSIK https://youtu.be/zfnRMIFHHrE WEBSITE www.chaoskinderpodcast.wordpress.com MAIL chaoskinderkontakt@gmail.com INSTA https://www.instagram.com/chaos.kinder/ FRANZÖSISCH "Le Chaos et ses enfants" https://podcasters.spotify.com/pod/show/lechaosetsesenfants

Tercera hora de Visión Global que dedicamos al análisis de Wall Street en el que nos acompaña Borja de Castro, analista de Banco Big. Con él miramos compañías como Micron Tecnologies, HelloFresh, VanEck Semiconductor ETF, Nio Inc - ADR, Spotify, AMD, Amazon, Adidas, Apple, Nvidia, General Motors, Alibaba, Infineon, Deckers, Ely Lilly, Home Depot, Carvana, Noble Corporation, Novo Nordisk, Royal Caribean, Glaukos Corporation y Mckesson Health, Después del consultorio de Wall Street hacemos un último repaso de los mercados al final de la cotización. Terminamos con el balance de la jornada en el que nos acompaña Samuel Abraldes, CEO de Socaire. Con él hablamos de las expectativas de cara a mañana, día intenso con el dato de IPC en EEUU y con la reunión de la Reserva Federal. También hablamos del APPLE y sus máximos históricos tras presentar su estrategia en torno a la IA y su acuerdo con OpenAI.

In our latest episode, host Dr. Rob Rothman interviews Greg Kunst, CEO of Aurion Biotech, to delve into the forefront of cell therapy for corneal disease. Join us to discover:Greg's journey from pivotal roles at Alcon and Glaukos to leading Aurion BiotechThe innovative allogenic cell therapy technology developed by AurionHow this technology addresses the global shortage of corneal tissueInsights into the challenges and breakthroughs in scaling production and securing market approvalFuture applications of cell therapy in ophthalmology beyond corneal endothelial diseaseDon't miss this fascinating conversation on the future of medical innovation in ophthalmology! Listen to the episode and subscribe to the OIS Podcast for more updates on the latest trends in eye care and medical technology.

In this episode, we talk with Mr. Mark Rhein, the Head of talent & Learning at Glaukos Corporation. Mark shares his experience in building a learning and development program at Glaukos, focusing on middle-level leadership development. He emphasizes the importance of prioritization and designing programs that provide the biggest value to employees. Mark also discusses the company's unique approach to performance management, which involves regular check-ins and feedback conversations. He shares insights on workforce planning and the need for flexibility in a rapidly growing organization. Overall, Mark highlights the importance of continuous learning and adapting to meet the needs of the business.TakeawaysPrioritize learning and development programs that provide the biggest value to employees.Design leadership development programs that focus on middle-level leaders, who have a direct impact on the majority of employees.Implement regular check-ins and feedback conversations as an alternative to traditional performance management.Streamline workforce planning and focus on critical roles and areas of expertise.Chapters00:00Introduction and Background01:12Building a Learning and Development Program at Glaukos Corporation05:01Focusing on Middle-Level Leadership Development07:23Designing and Implementing Leadership Development Programs09:16Expanding Learning Activities and Classes11:15Balancing Time Constraints with Learning and Development20:34Providing Feedback and Recognizing Achievements22:09Streamlining Workforce Planning32:27Lessons Learned and Advice for Building a Learning and Development Program35:27Exciting Innovations at Glaukos CorporationAbout Mark Rhein:https://www.linkedin.com/in/mark-rhein-7b3944/Mark has built a storied career over the last 25+ years building Learning & Development programs across industries. Deloitte, Sprint, Abbott, & now Glaukos are just some of the fine organizations Mark has contributed to. Mark's expertise, which I know we are going to dig into today, lies in the areas of Organizational Development, Performance Management, Leadership Development across all levels & project Management. Mark Holds his Bachelors degree in Enviornmental Design from the University of Missouri-Columbia & his Masters Degree in Executive Leadership & Organizational Change from Northwestern University.About Glaukos:www.glaukos.comGlaukos Corporation is a ophthalmic medical technology & pharmaceutical company based out of Southern California that is focused on novel therapies for the treatment of glaucoma, corneal disorders & retinal disease.

SummaryIn this episode, Mitch Robbins interviews Mark Rhein, The Head of Talent & Learning at Glaukos Corporation. Mark shares his experience in building a learning and development program at Glaukos focusing on middle-level leadership development. He emphasizes the importance of prioritization and designing programs that provide the biggest value to employees. Mark also discusses the company's unique approach to performance management, which involves regular check-ins and feedback conversations. He shares insights on workforce planning and the need for flexibility in a rapidly growing organization. Overall, Mark highlights the importance of continuous learning and adapting to meet the needs of the business.TakeawaysPrioritize learning and development programs that provide the biggest value to employees.Design leadership development programs that focus on middle-level leaders, who have a direct impact on the majority of employees.Implement regular check-ins and feedback conversations as an alternative to traditional performance management.Streamline workforce planning and focus on critical roles and areas of expertise.Chapters00:00Introduction and Background01:12Building a Learning and Development Program at Glauco's Corporation05:01Focusing on Middle-Level Leadership Development07:23Designing and Implementing Leadership Development Programs09:16Expanding Learning Activities and Classes11:15Balancing Time Constraints with Learning and Development20:34Providing Feedback and Recognizing Achievements22:09Streamlining Workforce Planning32:27Lessons Learned and Advice for Building a Learning and Development Program35:27Exciting Innovations at Glauco's CorporationAbout Mark:Mark has built a storied career over the last 25+ years building Learning & Development programs across industries. Deloitte, Sprint, Abbott, & now Glaukos are just some of the fine organizations Mark has contributed to. Mark's expertise, which I know we are going to dig into today, lies in the areas of Organizational Development, Performance Management, Leadership Development across all levels & project Management. Mark Holds his Bachelors degree in Enviornmental Design from the University of Missouri-Columbia & his Masters Degree in Executive Leadership & Organizational Change from Northwestern University.https://www.linkedin.com/in/mark-rhein-7b3944/About Glaukos:Glaukos Corporation is a ophthalmic medical technology & pharmaceutical company based out of Southern California that is focused on novel therapies for the treatment of glaucoma, corneal disorders & retinal disease.www.glaukos.com

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have several developments in the industry to discuss.First, Structure, a biotech company focused on obesity treatments, experienced a setback. The results from a phase 2 trial of their obesity pill fell short of expectations, causing the company's shares to plummet. Similarly, Radiopharma's drug for prostate cancer did not meet analysts' predictions for its benefit, which could accelerate a planned takeover by Eli Lilly.In other news, Illumina has decided to part ways with Grail, ending their battle with regulators. Activist investor Carl Icahn, who is suing Illumina over its acquisition of Grail, continues to push for the removal of several board members. Additionally, Pivotal Life Sciences has reloaded with $389 million and is now hunting for deals in a downturn, tracking startups in the biotechnology sector that need fresh funds to move their programs forward.Moving on, Zimvie is selling its spine business to H.I.G. Capital for $375 million. This strategic move allows Zimvie to focus on its dental business and reduce its debt. BTIG analysts are optimistic that the medtech industry will rebound in 2024 after a "string of rough years," despite rising interest rates and concerns about the impact of GLP-1 drugs and supply chain issues.Glaukos has received FDA approval for its drug-releasing eye implant to treat glaucoma. This product has the potential to revolutionize glaucoma treatment by addressing noncompliance with eye drops. Freenome has also started a 20,000-subject study of its lung cancer blood test, which could provide an alternative to CT imaging and reduce radiation exposure.Moving on to the healthcare industry, Elevance and Blue Cross Blue Shield of Louisiana (BCBSLA) are reviving their proposed $2.5 billion merger after addressing regulatory concerns. The No Surprises Act's dispute portal has reopened as the CMS faces challenges in rolling out the policy. A lawsuit has been filed in New Jersey alleging that the state's telehealth licensure rules hinder access to care, especially for patients with rare conditions.Cybersecurity concerns remain as connected devices used in telemedicine enable real-time patient monitoring and advanced care. CMS has sent a letter urging health plans and PBMs to ease up on independent pharmacies before a new policy goes into effect.In the biopharmaceutical sector, Roivant has faced setbacks but remains focused on expanding its pipeline. Babson Diagnostics has received FDA clearance for its blood testing technology, bringing us closer to Theranos-like blood testing.Overall, these developments highlight the challenges and strategic decisions made by companies in the Pharma and Biotech industry. Stay tuned for more updates in our next episode. Thank you for listening to Pharma and Biotech Daily.

Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See the full write ups for today's episode at nascentmc.com/podcastHere are the highlights: Belzutifan (Welireg) for RCC: - FDA approved belzutifan (Welireg) for advanced renal cell carcinoma (RCC) following prior treatments with PD-1/PD-L1 inhibitors and VEGF-TKI. Belzutifan is an HIF-2α inhibitor, the first novel therapeutic class for advanced RCC since 2015. Approval based on phase 3 LITESPARK-005 study data, granted to Merck Inc. Pulse Field Ablation (PFA) system for AFib: - FDA approved PulseSelect PFA system for atrial fibrillation (Afib) treatment. PFA uses electrical pulses to ablate cardiac tissue without thermal energy, reducing adverse events. Medtronic Inc. received approval. Roflumilast 0.3% (Zoryve) for Seborrheic Dermatitis: - FDA approved roflumilast foam 0.3% (Zoryve) for seborrheic dermatitis in individuals aged 9 and older. This is the first drug with a new mechanism of action for seborrheic dermatitis in over two decades. Approval supported by positive results from the STRATUM phase 3 trial, granted to Arcutis Biotherapeutics, Inc. Eflornithine (Iwilfin) for Neuroblastoma: - FDA approved eflornithine (Iwilfin) to reduce the risk of relapse in high-risk neuroblastoma patients. Eflornithine inhibits ornithine decarboxylase, reducing cell growth. Approval based on multi-site study results and granted to US WorldMeds, LLC. Isavuconazonium Sulfate For Pediatric Patients: - FDA approved isavuconazonium sulfate (Cresemba) for invasive aspergillosis and mucormycosis in pediatric patients. Provides an alternative to eye drops for glaucoma treatment, offering continuous delivery of travoprost. Approval based on Phase 3 trials and plans for label change, granted to Glaukos. Augmented Reality Smart Glasses Technology: - FDA approved NuLoupes augmented reality smart glasses with 3D stereoscopic imaging for dentistry and medicine. Offers live 3D stereoscopic imaging and plans to ship developer kits in 2024. Approval granted to NuEyes. OneRF Ablation System for Parkinson's: - FDA cleared the OneRF Ablation System for neurosurgical procedures in Parkinson's disease and other neurological conditions. Designed to capture electrical activity and selectively destroy brain tissue. Launch planned by NeuroOne in the first half of 2024. Pimicotinib For Tenosynovial Giant Cell Tumor: - FDA granted fast track approval to pimicotinib for the treatment of tenosynovial giant cell tumors. Demonstrated an overall response rate of 87.5% in a Phase 1b trial. Manufactured by Abbisko and commercialized in partnership with Merck. NDA for MDMA-Assisted Therapy for PTSD: - NDA submitted for MDMA in combination with psychotherapy for PTSD, aiming to be the first psychedelic-assisted therapy approved for PTSD. Submission by MAPS Public Benefit Corporation based on positive Phase 3 clinical trial results. Requested Priority Review of the NDA.

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, December 15, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. HeartBeam this week unveiled an artificial intelligence program for cardiac insights. Fast Five hosts Sean Whooley and Danielle Kirsh discuss the goal of the AI program and HeartBeam's technology that will be used in the program. Microbot Medical and Corewell are collaborating on telerobotics for endovascular surgical robotics. Hear what the goal of the collaboration is and what each company brings to the partnership. The FDA has approved Glaukos' iDose TR glaucoma-treating drug delivery implant. Whooley explains what the approval covers and how the company plans to launch the implant.  J&J's Biosense Webster treated its first patients in the company's dual-energy AFib ablation trial. The Fast Five hosts talk about the technology and some of the other AFib ablation companies in the playing field right now. Medtronic won a landmark FDA approval for its PulseSelect pulsed field ablation. Hear more about the approval, what PulseSelect is and when the company plans to start commercialization.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Glaukos, a medical technology company, has received FDA approval for its drug-releasing eye implant to treat glaucoma. This product is expected to revolutionize glaucoma treatment by addressing noncompliance with eye drops. Freenome, another medical technology company, has started a study of a blood test for lung cancer. The test could potentially serve as an alternative to CT imaging, which exposes patients to radiation. Tandem, a diabetes management platform, has completed the US launch of its revamped platform called Tandem Source. The platform combines the features of the company's legacy offerings with new data reports. In the wake of the Philips recall, two US senators are urging a review of FDA medical device oversight. The senators claim that Philips did nothing while patients suffered due to their sleep apnea devices. Medtronic has received approval for its pulsed field ablation (PFA) treatment for atrial fibrillation. PFA is considered a safer alternative to radiofrequency and cryoablation, and other companies like Boston Scientific and Johnson & Johnson are also pursuing the PFA market.The North Carolina Attorney General has sued HCA over degraded care quality at Mission Health. The lawsuit blames HCA for staffing and service shortages at the hospital.CMS has sent a letter to health plans and pharmacy benefit managers (PBMs) urging them to ease up on independent pharmacies. The letter asks payers to implement special payment arrangements with pharmacies before a new policy takes effect that could reduce upfront payments to pharmacies.CVS, Geisinger, and other healthcare organizations have signed a pledge committing to responsible use of artificial intelligence (AI) in healthcare.Nasdaq has ruled that Veradigm will not be delisted from the exchange as long as it complies with financial reporting requirements.Biogen receives positive recommendation from European regulators for its gene editing treatment Casgevy, while the clearance for Biogen's Skyclarys is uncertain.Novartis veteran Jay Bradner joins Amgen as its new chief scientific officer and head of R&D.The FDA expands the use of cancer drug Welireg to treat advanced kidney cancer.Fewer biotech companies are going public after a record run, but Fractyl Health becomes the first company in nearly a month to join the IPO queue.Moderna's cancer vaccine data leads to a share rally, with speculation that the company and partner Merck could seek approval before completing phase 3 testing.Patent protection will expire for many multibillion-dollar medicines this decade, prompting large pharma companies to find new products and markets.European regulators push for approval of CRISPR drugs.AstraZeneca and AbbVie are criticized by Elizabeth

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: CLICK HERE---Episode Overview: During this episode, we sit down with Dr. Clark Chang, Director of Global Medical Affairs at Glaukos, a pioneer in micro-invasive glaucoma surgeries. Motivated by enriching patient lives, Dr. Chang brings a clinician's perspective to advancing care for chronic eye diseases like keratoconus. While together, Dr. Chang shares insights into Glaukos' corneal cross-linking procedure, iLink, which halts disease progression and how this strengthens the cornea, allowing for visual optimization with specialty lenses. We also discuss the overwhelmingly positive patient feedback and Glaukos' mission of developing novel therapies. Tune in as Dr. Chang outlines key priorities like improving diagnosis and education to ensure patients receive timely, effective treatment. Join us to gain inspiration from his dedication to elevating patient's quality of life through persistence and collaboration. Let's go! Episode Highlights:Clark's clinical background motivates him to pursue upstream solutions for complex eye diseases.Glaukos' iLink cross-linking procedure halts keratoconus progression by strengthening the cornea.Overwhelmingly positive patient feedback shows the impact on quality of life.Priority areas are improving diagnosis and education around eye disease.Clark exemplifies persistence and commitment to elevating patient care through collaboration.About our Guest: Clark Chang, OD, MSA serves as the director of global medical affairs at Glaukos. He pursued both Doctor of Optometry and Master of Science degrees in Low Vision Rehabilitation. After the completion, Dr. Chang undertook additional residency training in the area of primary care to augment his knowledge in the management of ocular pathologies. Dr. Chang's residency training culminated his interest in the cornea and contact lenses, which led to the completion of his fellowship in Cornea and Contact Lens at The Cornea and Laser Eye Institute.In addition, he has been involved in many clinical studies, during both his residency and fellowship. Dr. Chang lectures both nationally and internationally. At the Cornea and Laser Eye Institute and its Center for Keratoconus, Dr. Chang concentrated on providing preoperative and postoperative care for refractive surgery patients and participants in onsite clinical trials. He also specializes in designing specialty contact lenses for optical rehabilitation in patients with various corneal conditions including keratoconus, ectasia, post-intacs, post-collagen cross-linking, post-corneal transplantation, and post-ocular trauma.Links Supporting This Episode:Glaukos Website: CLICK HEREGlaukos LinkedIn page: CLICK HEREGlaukos Twitter page: CLICK HERE Mike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK...

Tivic Health's successful pricing of a $2.1 million offering reflects investor confidence in the company's innovative medical device solutions. The offering comes just days after the company closed another $1.8 million offering of common stock. Fast Five hosts Sean Whooley and Danielle Kirsh discuss what the offer includes and when it will close.  The collaboration between Glaukos and Radius XR signifies the growing adoption of wearable diagnostics in ophthalmology, aiming to improve disease monitoring and personalized patient care. Hear more about the wearable diagnostic platform and the terms of the collaboration agreement.  IR-MED recently announced positive interim results from a clinical study of its PressureSafe noninvasive, handheld optical monitoring device. Whooley gives an inside look at some of the key findings of the study, as well as what the device does. Philips initiated a repurchasing program to cover certain obligations arising from long-term incentive plans. Learn about how much money is involved in the program and the timelines associated with it. The adoption of the Asensus surgical robot platform by a leading U.S. hospital for pediatric procedures showcases the expanding application of robotic-assisted surgery in specialized areas of medicine. Kirsh and Whooley discuss the surgical robotic platform and what makes it compatible with pediatric patients. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

Dr. Clark Chang is a cornea and keratoconus, KC, specialist at Wills Eye Hospital in Philadelphia and the Director of Global Medical Affairs at Glaukos. Keratoconus is a disease of the eye where tissue thins and gradually bulges outward into a cone-like shape.  While changes in the cornea are small, vision becomes very blurry, and the underlying cause may be overlooked. Glaukos has introduced the iLink procedure, a minimally invasive outpatient procedure to slow or halt the progression of this disease and help patients preserve their vision. Clark explains, "It is associated with age, but it's in the different group of people than most of your audience is thinking. We're very familiar with conditions like age-related macular degeneration. Everybody knows that because it's very impactful to one's vision, and the fear of loss of vision has frequently been rated as one of the top one or two biggest fears in a person's life. Most diseases are age-related in that they can occur with time. This disease more commonly occurs during puberty or in younger patients."    "In order to be able to diagnose this condition, especially at an early stage when there is an extremely small amount of change in the alteration in the shape of the cornea, you really need sophisticated diagnostic technology that we usually call topographer or tomographer. Basically, it maps out the shape of the cornea, either just at the front or front and back of your cornea. Being able to, in a more sensitive way, figure out whether or not there's any small amount of area that's becoming misshapen more than what a normal cornea or tissue would look like." #Glaukos #Keratoconus #iLink #CornealCrossinglinking #EyeHealth #KCAwareness #LivingwithKeratoconus #EyeDisease #Cornea  glaukos.com Download the transcript here

Dr. Clark Chang is a cornea and keratoconus, KC, specialist at Wills Eye Hospital in Philadelphia and the Director of Global Medical Affairs at Glaukos. Keratoconus is a disease of the eye where tissue thins and gradually bulges outward into a cone-like shape.  While changes in the cornea are small, vision becomes very blurry, and the underlying cause may be overlooked. Glaukos has introduced the iLink procedure, a minimally invasive outpatient procedure to slow or halt the progression of this disease and help patients preserve their vision. Clark explains, "It is associated with age, but it's in the different group of people than most of your audience is thinking. We're very familiar with conditions like age-related macular degeneration. Everybody knows that because it's very impactful to one's vision, and the fear of loss of vision has frequently been rated as one of the top one or two biggest fears in a person's life. Most diseases are age-related in that they can occur with time. This disease more commonly occurs during puberty or in younger patients."    "In order to be able to diagnose this condition, especially at an early stage when there is an extremely small amount of change in the alteration in the shape of the cornea, you really need sophisticated diagnostic technology that we usually call topographer or tomographer. Basically, it maps out the shape of the cornea, either just at the front or front and back of your cornea. Being able to, in a more sensitive way, figure out whether or not there's any small amount of area that's becoming misshapen more than what a normal cornea or tissue would look like." #Glaukos #Keratoconus #iLink #CornealCrossinglinking #EyeHealth #KCAwareness #LivingwithKeratoconus #EyeDisease #Cornea  glaukos.com Listen to the podcast here

I. Paul Singh, MD, hosts this special edition of CRST: The Podcast to discuss research surrounding the iStent inject (Glaukos) with Kevin Gillmann, MD, MBBS, FEBOphth, MArch, PgCert (HMS). Dr. Gillmann shares his clinical experience with the iStent inject and highlights details of a published study that examines the device's effect on IOP and the anatomical structure of Schlemm canal based on OCT imaging. He explains the importance of the position of the iStent and its effect on clinical outcomes. [More Information]

Medical device analyst at Gabelli Funds, Jennie Tsai, shares why Glaukos Corp. is one of our best ideas for 2023.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, sit down with Gavin Herbert, Tom Burns, Andy Corley and Tom Mitro to discuss their days at Allergan and what they have learned from their experiences. Welcome to the Eyeluminaries podcast :37 News and notes with John and Jim 1:01 Viatris to acquire Oyster Point, Famy Life Sciences 1:06 Ocuphire enters global license agreement with Famy for Nyxol development 4:20 Eyenuk secures $26 million in Series A funding 6:24 Encapsulated cell therapy shows positive results for macular telangiectasia 8:31 Introduction of the Allergan alumni 10:35 The interview 12:10 Gavin Herbert – what is the secret to great leadership? 12:18 Tom Burns – what have you learned from Allergan that has led to your success? 17:48 Andy Corley 20:38 Tom Mitro 24:50 Jim Mazzo 29:41 Herbert – principles 30:29 Corley – producing jobs 32:01 Herbert – alumni 32:50 Wrap up and a preview of episode 10 33:38 Feedback, questions and guest suggestions at eyeluminaries@healio.com 34:06 Thanks for listening 34:14 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Gavin Herbert is a board member of the Doheny Eye Institute and the Nixon Foundation, as well as a life trustee of the University of Southern California. He was the co-founder and chief executive officer of Allergan Inc. Tom Mitro is the past president and chief operating officer at Aerie Pharmaceuticals. Tom Burns serves as the chief executive officer and the chairman of the board for Glaukos. Andy Corley is the founder of Yelroc Consulting, Inc. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Herbert reports being a board member of the Doheny Eye Institute and the Nixon Foundation, as well as a life trustee of the University of Southern California. He was the co-founder and chief executive officer of Allergan Inc. Mitro is the past president and chief operating officer at Aerie Pharmaceuticals. Burns serves as the chief executive officer and the chairman of the board for Glaukos. Corley is the founder of Yelroc Consulting, Inc.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Sean Ianchulev, MD, MPH. Welcome to the Eyeluminaries podcast :01 A review of the previous episode :23 News and notes with John and Jim 1:31 Alcon to acquire Aerie Pharmaceuticals 1:40 Glaukos, iVeena enter licensing agreement for keratoconus treatment 5:20 Lions Eye Institute to acquire SightLife 8:37 Novaliq submits NDA for CyclASol for treatment of dry eye disease 11:37 AbbVie, iSTAR enter alliance to support MINIject MIGS device 13:30 Introduction of Sean Ianchulev 16:30 The interview 18:37 Impact on Google Glass 21:32 What innovations are you proud of and what projects are you excited about? 26:20 What advice do you have for new entrepreneurs? 33:04 How do you balance your work life and your home life? 36:24 Legends in the field of ophthalmology 38:07 Give feedback at eyeluminaries@healio.com 39:39 A preview of the next episode of Eyeluminaries 39:54 Thanks for listening 40:26 Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can find Dr. Ianchulev on LinkedIn: Sean Ianchulev, MD, MPH. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

I. Paul Singh, MD, continues this special edition segment of CRST: The Podcast with J. David Stephens, MD, and Savak Teymoorian, MD, MBA. In this episode, the panel focuses on pearls and techniques for using the iStent inject W (Glaukos). Watch to gain expert insights into how to position patients to obtain an adequate view, achieve proper seating of the iStent inject W, and fine-tune your technique. [More Information] I. Paul Singh, MD; J. David Stephens, MD; and Savak Teymoorian, MD, MBA

Tauchen wir ab, mit den Nereiden auf den Hippokampen, schwimmen von einem grün bewachsenen Strand zu einer Höhle im Atlas, durch die Meerenge zwischen Skylla und Charybdis und bis zum kristallenen Palast des Poseidon. In dieser Folge geht es um viele Meerwesen - Monster, Tiere und Götter. Für Hinweise oder Feedback schreibt mir gerne auf: www.chaoskinderpodcast.wordpress.com Oder an: chaoskinderkontakt@gmail.com Instagram: @chaos.kinder Spenden könnt ihr hier: PAYPAL Mit: Poseidon, Zeus, Hades, Kronos, Titanomachie, Pferde, Robben, Hippokampen, Amphitrite, Protheus, Nereus, Doris, Nereiden, Athene, Medusa, Hera, Persephone, Phorkys, Keto, Gorgonen, Graien, Skylla, Glaukos, Charybdis, Pegasus, Chrysaor, Perseus, Zirze, Leukothea/Ino, Palaimon/Melikertes.

Tauchen wir ab, mit den Nereiden auf den Hippokampen, schwimmen von einem grün bewachsenen Strand zu einer Höhle im Atlas, durch die Meerenge zwischen Skylla und Charybdis und bis zum kristallenen Palast des Poseidon. In dieser Folge geht es um viele Meerwesen - Monster, Tiere und Götter. Für Hinweise oder Feedback schreibt mir gerne auf: www.chaoskinderpodcast.wordpress.com Oder an: chaoskinderkontakt@gmail.com Instagram: @chaos.kinder Spenden könnt ihr hier: PAYPAL Mit: Poseidon, Zeus, Hades, Kronos, Titanomachie, Pferde, Robben, Hippokampen, Amphitrite, Protheus, Nereus, Doris, Nereiden, Athene, Medusa, Hera, Persephone, Phorkys, Keto, Gorgonen, Graien, Skylla, Glaukos, Charybdis, Pegasus, Chrysaor, Perseus, Zirze, Leukothea/Ino, Palaimon/Melikertes.

In this episode, David W. Parke II, MD, sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss stepping down as the American Academy of Ophthalmology CEO, the highlights of what he accomplished during this time, and his thoughts on the future of ophthalmology. Welcome to the Eyeluminaries podcast :10 News and notes with John and Jim 1:30 Allergan's Vuity presbyopia-correcting drop gains FDA approval 1:36 Glaukos' two phase 2 clinical trials for dry eye disease and presbyopia 3:30 Acufocus' receives “approvable” letter on IC-8 IOL 5:42 Harrow Health acquires four ophthalmic drugs from Novartis 8:40 Welcome David Parke 10:54 What's it like having three generations of ophthalmologists in your family? 11:27 Why leave the AAO presidency now? What's the significance of 2022? 13:29 Tell us some of the highlights what are you most proud of during those past years 16:18 What are your thoughts on the consolidation from private equity? 19:55 As you look ahead to the future of ophthalmology, what worries you the most and what excites you the most, David? 25:17 What are your thoughts on the future of meetings? 31:23 Tell our listeners a little bit about what Verana Health does and what you'll be doing there 35:49 Thank you, David Parke! 40:26 Thanks for listening 41:00 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss Meditec and AMO. David W. Parke II, MD, is chairman of the board at Verana Health and former CEO of the American Academy of Ophthalmology. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Acufocus, Allergan, Glaukos and Novartis who were mentioned in this episode. Mazzo reports being an adviser for Anivive Lifesciences, Avellino, Bain Capital, CVC Capital, Zeiss Labs; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Centricity Vision, Crystilex, IanTech, Lensgen,  and Visus. Parke reports a financial interest in Verana Health.   

Paris was on a walk in Minnesota last year and decided to look inside a Little Free Library on the road. Within it, she found Emblem: Unity, flipped it open to a random page, and knew the luck of Terriblo was with her that day. Content Warnings: In addition to our usual barnyard language, this episode includes discussions around animal violence, parental abuse, bad mental health advice, and suicide.

Thank you for your support for Season 2! We reflect and look forward to Season 3 on this episode! Learn more about our co-hosts below! Alok Tayi, PhD is the Co-founder and CEO of Vibe Bio. Vibe is a therapeutics company that partners with patient communities to develop new medicines. Previously, Alok spent 10 years as an entrepreneur and life sciences software executive. He started and built the Life Sciences business unit at Egnyte, was a YCombinator-backed founder and started two SaaaS companies. Prior to his career in software, Alok spent over 15 years as a scientist, including postdoctoral work at Harvard University with George Whitesides. Alok holds a PhD from Northwestern University and BS from Cornell University. Rahul Chaturvedi is the Founder and CEO of Clora, the leading marketplace where people go to discover, build, and manage on-demand life science teams. Prior to founding Clora in 2017, Rahul was the head of clinical development at several biopharma companies, such as Kaleido Biosciences (NSDQ: KLDO) and Avedro (acquired by Glaukos). Rahul has successfully led the development activities for 20+ Phase II/III programs that have resulted in 6 product approvals to date. Rahul holds a bachelor of science degree from Brandeis University.

Adrienne Graves, PhD, former CEO of Santen, opened this panel discussion by reiterating a sentiment expressed by surgeons, innovators, and investors: we're in the middle of a glaucoma renaissance. The release of new devices, instruments, and pharmaceuticals has led to improvements in surgical procedures and other treatment options that promise to improve the lives of glaucoma patients.For this week's discussion, originally recorded for the OIS Glaucoma Innovation Showcase, Dr. Graves corralled four ophthalmology leaders to discuss what's new and what's next in glaucoma innovation, how their companies stay resilient through the SARS-CoV-2 pandemic, and more.A glimpse: Jay Katz, MD, Chief Medical Officer of Glaukos, shared the latest news on the iDose® TR sustained-release travoprost implant and the iStent Infinite, an investigational device designed to reduce IOP in open-angle glaucoma patients.New World Medical, which focuses on glaucoma surgical devices, has three products launched and two in the pipeline. Santen,  developer of everything from drops to surgical solutions, is exploring new MOAs and preparing for Phase III clinical trials for PRESERFLO, a microshunt currently available in Europe and under FDA review. Allergan, part of AbbVie for a little over a year, has gotten DURYSTA, its biodegradable implant, into the hands of 2,000 physicians to date according to Ramin Valian.Listen to the full episode to hear the panel address the following:What would you like your company to focus on for glaucoma?How has COVID-19 affected your product development, marketing, and physician interactions?How are your companies part of the glaucoma solution?The podcast lineup includes:Adrienne Graves, PhD, former CEO of Santen (moderator)Jay Katz, MD, Chief Medical Officer, GlaukosBilal Khan, CEO of New World MedicalOmar Sadruddin, MD, Senior Medical Director of SantenRamin Valian, Vice President, Glaucoma, Surgical, Retina & Eye Care Portfolio-U.S., at Allergan, an AbbVie CompanyHit “Play” to Listen.

Baruch (Barry) Kupperman, MD, PhD, works as a consultant, professor, and benchtop scientist, but finds the most meaning in the dozens of patients he treats each week.With research interests in dry AMD and drug delivery, Dr. Kupperman held multiple roles in University of California Irvine's Department of Ophthalmology before becoming the Roger F. Steinert Professor and Chair of the Department of Ophthalmology School of Medicine in 2017. Although he spends more time in leadership meetings these days, Dr. Kupperman still devotes time to the pursuit of science and medicine.OIS host Firas Rahhal, MD catches up with Dr. Kupperman after a rare two days off to discuss his career path, the current and future state of drug delivery, and what keeps him awake at night. Dr. Kupperman also discusses his residency and first fellowship (he completed three), which involved treating AIDS patients with retinitis. Administering eye injections to patients weekly — even seeing patients at home when they were too sick to visit the clinic — motivated him to help establish a drug delivery unit at UC Irvine to research more convenient ways to deliver treatments.Listen to the podcast today to discover:More about Dr. Kupperman's background, his work with AIDS patients, and his purposeful detour into neuroscience.The evolution of drug development and delivery to date and his views on the current state of drug delivery into the retina. He also names the three most promising long-term developments in ophthalmic research.The breadth of innovation happening in Orange County and UC Irvine's influence in furthering that innovation. The university's Gavin Herbert Eye Institute spun off several companies, including Glaukos, which developed the first Micro-Invasive Glaucoma Surgery (MIGS) device, iStent, which is now FDA-cleared and commercially available. UC Irvine is also behind stem cell companies and many others.

Dr. Rajesh Rajpal, MD, Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision discusses the launch and availability of their TECNIS Synergy™ in the United States and Canada. This next-generation presbyopia-correcting intraocular (PC-IOL) lens offers cataract patients the widest range of continuous vision, and best near vision among leading PC-IOLs, without the visual gaps seen with some multifocal technology. He talks about how this new next-gen lens was developed​,​ designed​,​ and the science behind it​, as well as other innovations in eye care solutions.​ #TECNISSynergy #Cataracts Rajesh Rajpal, M.D. is Chief Medical Officer and Global Head of Clinical and Medical Affairs for Johnson & Johnson Vision. In this role, Dr. Rajpal leads the integration of rapidly evolving medical and clinical insights into new product development to address unmet needs of patients and eye care professionals around the world. He also oversees clinical trials and the generation of surgical and vision care evidence and serves as the critical liaison to government agencies and to the academic, scientific, and industry communities. Dr. Rajpal joined Johnson & Johnson Vision in 2020 from Avedro (acquired by Glaukos), where he served as Chief Medical Officer. He was a member of the senior executive team that led to an IPO and subsequent acquisition and directly oversaw clinical operations, medical affairs, regulatory affairs, and professional relations for professional societies and clinicians. Active in research and professional education, Dr. Rajpal has served as principal investigator in numerous clinical trials, authored multiple original peer-reviewed publications and textbook chapters, and has lectured internationally on topics related to corneal disease, cataract and refractive surgery. In addition to others, he is a recipient of the Senior Achievement and Secretariat awards from the American Academy of Ophthalmology. He currently holds appointments on the clinical faculties of Georgetown University Medical Center and Virginia Commonwealth University and serves as the Cornea Consultant to the Walter Reed National Military Medical Center. He is certified by and is a Diplomate of the American Board of Ophthalmology. He is a member of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery, Cedars/Aspens, AECOS, and the International Society of Refractive Surgery. Additionally, he has served as President and on the Board of Directors of the Washington D.C. Ophthalmology Society. He is the founder of the See Clearly Vision Group, an ophthalmology and optometry group practice with multiple offices in the metropolitan Washington, DC area. Dr. Rajpal has been regularly recognized as a Top Doctor by Washingtonian Magazine, Northern Virginia Magazine, and Consumers' Research Council of America. He was the first eye surgeon in Washington, D.C. to perform Laser Vision Correction as part of the clinical trials for FDA approval.

In this episode, Rick Eiswirth, president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology. Intro :13 In this episode :18 About Rick Eiswirth :23 What’s your background? How did you get into the ophthalmology industry? 0:51 What are the benefits of Iluvien (fluocinolone acetonide intravitreal implant, Alimera Sciences)? Is this an ideal treatment for 2021? 3:36 How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs’ predominance? 6:26 Can you tell us more about the New Day trial? 8:10 Which trial outcome would be considered a success for Iluvien? 11:58 Do you anticipate a cost savings? 13:58 What’s the status of the New Day trial? 15:15 How has COVID changed the industry landscape in ophthalmology? 16:20 Are there any new products in the pipeline? 18:38 Iluvien is approved in other countries for uveitis 20:36 What have you seen from retina specialists; are there longer efficacy rates? 22:10 What do you think is the most important challenge the ophthalmic community will face in the future? 23:17 Thanks for listening 24:36 Rick Eiswirth is president and CEO of Alimera Sciences. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Eiswirth is president and CEO of Alimera Sciences. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.

Books 5-9 - First Turning Point Book V: Diomedes Fights the Gods  Aristeia (book 6) Glaukos and Diomedes - two enemies, two guest-friends, ancestry and kinship bind beyond political interests. Book VI: Hector and Andromache  Male/Female dynamics: Achilles/Briseis, Hector/Andromache, Paris/Helen Male tenderness, husbandman, father, countryman, duty before self  Book VII: Ajax against Hector  Book VIII: The Trojans at the Wall  Book IX: The Embassy to Achilles Greeks are losing. Realize they must do something. Seek Achilles.  Achilles rejects reason, family, friends, tradition, decency, society, and the cosmos.

In this episode, Cathleen M. McCabe, MD, chief medical officer of Eye Health America, shares her insights and perspectives on intraocular lenses, MIGS, dry eye and more. Intro :14 In this episode :21 About Cathleen M. McCabe, MD :28 What is your favorite intraocular lens implant to use and why? 2:24 What is your favorite minimally invasive glaucoma surgery (MIGS) to use and why? 4:03 What is your favorite dry-eye treatment to use and why? 4:49 What’s your preferred technique for secondary IOLs? 6:29 How has the role of women in ophthalmology changed throughout the years? 8:46 How did you get involved with international work? How has the pandemic affected this? 10:55 Tell us about your mission work. What are you currently involved in? 12:54 What is the most important topic/issue/challenge facing ophthalmology now or in the future? 15:11 Final words from Dr. McCabe 16:46 Cathleen M. McCabe, MD, is chief medical officer of Eye Health America; medical director of The Eye Associates and president of Outpatient Ophthalmic Surgery Society. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. To learn more about the Global Education & Research Society of Ophthalmology (or GERSO), visit https://www.gerso.org. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.

Thank you for your support for Season 1! We reflect and look forward to Season 2 on this episode! Learn more about our co-hosts below! Alok Tayi is the Vice President of Life Sciences at Egnyte where he is responsible for building and executing the company's strategy for the life sciences market segment. Alok works across the organization to verticalize our marketing, sales, product, compliance, and account management practices for this domain. Before joining Egnyte, Alok was a YCombinator-backed entrepreneur and started two vertical software-as-a-service companies. Prior to his career in software, Alok spent over 15 years as a scientist: he took part in postdoctoral work at Harvard University with George Whitesides, and has published papers in Nature and Nature Chemistry. Alok holds a PhD from Northwestern University and BS from Cornell University. Rahul Chaturvedi is the Founder and CEO of Clora, the leading marketplace where people go to discover, build, and manage on-demand life science teams. Prior to founding Clora in 2017, Rahul was the head of clinical development at several biopharma companies, such as Kaleido Biosciences (NSDQ: KLDO) and Avedro (acquired by Glaukos). Rahul has successfully led the development activities for 20+ Phase II/III programs that have resulted in 6 product approvals to date. Rahul holds a bachelor of science degree from Brandeis University.

In the second episode of season 2 of the Make Marketing Easy podcast, host Joel Gaslin talks to Andy Wright, Sr. Regional Business Manager with Glaukos. To open, Andy explains how he realized that LinkedIn is a great avenue to get information out about his company. He began by asking surgeons he worked with to pose for pictures with their ... Read More The post A Veteran Medical Device Sales Rep Explains How He Uses Social Media to Help Him Succeed appeared first on Make Marketing Easy.

In this episode, we bring you pearls and perspectives from Hawaiian Eye 2020.    Ashley Brissette, MD, MSc, FRCSC, considers the importance of testing for inflammation and dry eye before performing cataract surgery :17 Ryan Bleeks, of Sun Ophthalmics, shares an update on Cequa - cyclosporine ophthalmic solution 0.09% - for the treatment of dry eye disease 2:45 Jay S. Pepose, MD, PhD, discusses treatment options for varicella zoster 4:04 Jennifer M. Loh, MD, discusses the impact that sharing a meibomian gland image can have in patient treatment 6:04 Brandon Ayres, MD, examines the use of the FDA-approved epi-off corneal cross-linking procedure 7:16 John P. Berdahl, MD, discusses the benefits of compounded medications that are unique to ophthalmology 10:18 Femida Kherani, MD, shares pearls for incorporating dermal fillers and neuromodulators 12:13 Craig N. Piso, PhD, shares pearls for improving ophthalmic technician performance 13:01 Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses results of the MOST phase 4 trial 14:30 Richard S. Davidson, MD, discusses surgical correction for keratoconus 15:43 Steven D. Vold, MD, discusses the use of Vyzulta -latanoprostene bunod ophthalmic solution 0.024% by Bausch + Lomb 17:00 Thanks for listening 18:45 Disclosures: Ayres reports being a paid consultant to Glaukos. Bleeks is an employee of Sun Ophthalmics. Brissette reports being a paid consultant to Alcon and Zeiss. Loh reports being a paid consultant to Sight Sciences. Mitro is president and COO of Aerie Pharmaceuticals. Vold reports being a paid consultant to Bausch + Lomb. Davidson, Kherani, Pepose and Piso report no relevant financial disclosures.

In this lecture, we discuss (a) the concept of xenia and (b) its relation to Glaukos and Diomedes' strange interaction and exchange, and (c) we conclude by observing Hektor back in Troy meeting Hekabe, Helen (and Paris), and his wife Andromache. --- Send in a voice message: https://anchor.fm/alexander-schmid9/message Support this podcast: https://anchor.fm/alexander-schmid9/support

TV: Mikael Svensson, förvaltare på C Worldwide Healthcare Select är nyss hemkommen från USA. I ett samtal med Placeras Jesper Norberg berättar Mikael om sina intryck från resan och lyfter fram några av de 28 hälsovårdsföretag han träffade. Aktier som diskuteras är bland annat Dexcom, Glaukos och Oncopeptides.

In dieser Folge geht es um Aphrodite, Glaukos, Bellaross, Hipponoos, Bellerophon, Pegasos, Proitos, Anteia und Poseidon.

Chris Calcaterra, COO of Glaukos, revisits the company’s recent good fortune at the FDA, which approved its second generation iStent inject. What’s next for Glaukos? Calcaterra walks OIS Podcast listeners through the company’s “Five in Five” pipeline. In a follow up to the interview, Calcaterra also reacts to Alcon’s decision to recall CyPass. How will this impact Glaukos? Does he have any concerns?

In this episode, we observe (a) a cruel moment with Agamemnon, (b) an odd exchange between Diomedes and Glaukos, and (c) Hektor's final trip to Troy (Ilion). --- Send in a voice message: https://anchor.fm/alexander-schmid9/message Support this podcast: https://anchor.fm/alexander-schmid9/support

Episode 116: Paul Madera – Why He Invested $10 Million In Facebook In 2005 Paul Madera is one of the most down to earth and humble people I’ve ever spoken to… Considering the immense level of success in multiple life categories, I initially expected that he would have at least a semblance of an ego.  As you’ll hear, that does not exist within Paul.  What a refreshing and enjoyable conversation on this episode of The Learning Leader Show. Paul Madera is the founder of Meritech (1999).  Meritech is known as the pioneer of late stage investing. Paul currently focuses on the SaaS, storage, e-commerce, financial technology, digital consumer, and medical device sectors.  In 2005, Paul sat down with Facebook CEO Mark Zuckerberg and made the decision to invest $10 million to earn 2% of Facebook at the time ($500m valuation).  As most people know, Facebook is now worth hundreds of billions of dollars.  Paul also led the charge for Meritech to be an early investor in Salesforce.com among many other great decisions. Paul holds a B.S. from the United States Air Force Academy and an M.B.A. from the Stanford Graduate School of Business, and currently serves as the Chairman of the US Air Force Academy Endowment. Previously he flew F 16’s on missions that included dropping bombs on targets and dealing with enemy aircrafts (dogfighting). Episode 116: Paul Madera – Why He Invested $10 Million In Facebook In 2005 Subscribe on iTunes  or Stitcher Radio The Learning Leader Show “I Love To Invest In Leaders Who Are Obsessed About Their Company.  Those Who Absolutely Love What They Are Doing.” In This Episode, You Will Learn: The most dedicated, focused individuals who stress personal excellence tend to sustaine excellence Why Paul initially wanted to invest in MySpace What his first thoughts of Facebook CEO Mark Zuckerberg were in 2005 Agreeing to a deal with Mark Zuckerberg – Investing $10m at a $500m company valuation How his company makes decisions on who to invest in The specific qualities he looks for in a CEO to invest in (He loves leaders who are obsessed with their company and certain of their future success) The biggest mistakes young leaders/managers make The specific missions he flew as a fighter pilot – dropping bombs on enemy targets and dealing with combative opposing aircrafts Dogfighting like they did in the movie “Top Gun” – incredible stories! Great leaders are always “doing” – Always striving to learn more  “It’s Important To Have a Commitment Strategy… Not An Exit Strategy” Continue Learning: Go To: MeritechCapital.com See Paul on The Forbes Midas List: Forbes Midas List: Paul Madera Connect with Paul on LinkedIn: com/in/paulmadera To Follow Me on Twitter: @RyanHawk12 You may also like these episodes: Episode 001: How To Become A Master Connector W/ Jayson Gaignard From MasterMind Talks Episode 078: Kat Cole – From Hooters Waitress To President of Cinnabon Episode 082: Dan Pink – The Science of Motivation, Legendary Writer & Ted Talk Episode 086: Seth Godin – How To Become Indispensable & Build Your Tribe Did you enjoy the podcast? If you enjoyed hearing Jay Baer on the show, please don’t hesitate to send me a note on Twitter or email me. Episode edited by the great J Scott Donnell Bio From MeritechCapital.com Paul Madera founded Meritech in 1999. He currently focuses on the SaaS, storage, e-commerce, financial technology, digital consumer, and medical device sectors. He has led Meritech's investments into 2Wire (Pace), Acopia (F5), BlueArc (Hitachi Data), DataStax, DealerSocket, Facebook (FB), Force10 Networks (DELL), Glaukos, Homestead Technologies (INTU), IntraLase (AMO), Openlane (KAR), Panzura, Prosper, Riverbed Technology (RVBD), Salesforce.com (CRM), Tegile, Tensilica (CDNS), Topspin (Cisco), Wonga, Yammer (MSFT) and 21Vianet (VNET). Prior to Meritech, Paul was Managing Director and Head of the Private Equity Group at Montgomery Securities/Banc of America where he assisted tech and consumer-based startups in raising capital. He began his career in finance as an investment banker with Morgan Stanley & Co. in New York. Before joining Morgan Stanley, he served in the United States Air Force as an F-16 Instructor Pilot based in South Korea, Spain, and Utah. He also spent a tour at the Pentagon as a member of the Air Force Legislative Liaison Office. Paul holds a B.S. from the United States Air Force Academy and an M.B.A. from the Stanford Graduate School of Business, and currently serves as the Chairman of the US Air Force Academy Endowment. Paul spends his off hours cycling the hills west of Palo Alto to prepare for "century" rides as well as jogging throughout the San Francisco Peninsula (when he is not gathering material to terrorize his partner Mike Gordon).

MIGs leader Glaukos Corp. raised over $100 million in an IPO to expand its already command-ing reach in the white hot MIGs Market. Now the company commands a market capitalization close to $1 billion, enriching the venture investors who committed more than $100 million in ven-ture capital to the company. CEO Thomas Burns explains how Glaukos got where it is today and where he sees it – and the entire MIGs market - going.

In Kreta hat praktisch die ganze abendländische Kultur begonnen. Auch der Mythos bezieht sich immer wieder auf Kreta - so auch die Geschichte von Glaukos: Sie spielt auf Kreta, auf dem Hof des Königs Minos.